本文選題：結(jié)核性胸膜炎 + 尿激酶��； 參考：《廣東醫(yī)學(xué)》2014年10期

【摘要】：目的觀察胸腔內(nèi)注射尿激酶對結(jié)核性胸膜炎患者纖溶活性及胸膜肥厚的影響。方法 60例結(jié)核性胸膜炎患者分成尿激酶組和對照組,兩組均予胸腔置管引流,并予3HRZE/9HR方案抗結(jié)核治療,尿激酶組同時(shí)予胸腔內(nèi)注射尿激酶。兩組均于引流前后檢測胸腔積液纖溶酶原激活劑抑制因子-1、組織型纖溶酶原激活物、Ⅲ型前膠原(PCⅢ),并于治療結(jié)束時(shí)測定胸膜厚度。結(jié)果尿激酶組治療后胸腔積液纖溶活性增高,PCⅢ下降。對照組治療前后纖溶活性無明顯變化,PCⅢ雖下降,仍高于尿激酶組。尿激酶組在胸膜厚度及粘連發(fā)生率均顯著低于對照組。結(jié)論胸腔內(nèi)注射尿激酶能增高胸腔積液纖溶活性及降低PCⅢ濃度,能減輕胸膜肥厚及減少胸膜粘連。
[Abstract]:Objective to observe the effect of intrathoracic injection of urokinase on fibrinolytic activity and pleural hypertrophy in patients with tuberculous pleurisy. Methods 60 patients with tuberculous pleurisy were divided into two groups: urokinase group and control group. Both groups were treated with thoracic tube drainage and 3HRZE / 9HR regimen. Urokinase group was treated with intrathoracic injection of urokinase. The plasminogen activator inhibitor -1 in pleural effusion, tissue plasminogen activator and type 鈪，

本文編號：2017340